

EDITORIAL

- 1953 A call to action: overcoming anxiety through active coping**
Joseph E. LeDoux and Jack M. Gorman

REVIEWS AND OVERVIEWS

- 1956 The fate of integrated treatment: whatever happened to the biopsychosocial psychiatrist?**
Glen O. Gabbard and Jerald Kay

INTROSPECTIONS

- 1964 Husbands and wives**
Richard G. Druss

CLINICAL CASE CONFERENCE

- 1966 Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington's disease**
David M. Blass, Martin Steinberg, Iracema Leroi, and Constantine G. Lyketsos

IMAGES IN PSYCHIATRY

- 1973 Carl Gustav Jung, MD, 1875–1961**
Essay by Sam C. Naifeh

NEW RESEARCH – ARTICLES

- 1974 Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study**
Jonathan Davidson, Teri Pearlstein, Peter Londborg, Kathleen T. Brady, Barbara Rothbaum, Jon Bell, Richard Maddock, Mark T. Hegel, and Gail Farfel
- 1982 Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study**
Randall D. Marshall, Katherine L. Beebe, Mary Oldham, and Rocco Zaninelli

- 1989 An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder**
Michael W. Otto, Kimberly S. Tuby, Robert A. Gould, Renée Y.S. McLean, and Mark H. Pollack

- 1993 Emotion-focused psychotherapy for patients with panic disorder**
M. Katherine Shear, Patricia Houck, Catherine Greeno, and Sophia Masters

- 1999 Impact of generalized social anxiety disorder in managed care**
David J. Katzelnick, Kenneth A. Kobak, Thomas DeLeire, Henry J. Henk, John H. Greist, Jonathan R.T. Davidson, Franklin R. Schneier, Murray B. Stein, and Cindy P. Helstad

- 2008 Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder**
Moirra A. Rynn, Lynne Siqueland, and Karl Rickels

- 2015 Low level of brain dopamine D₂ receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex**
Nora D. Volkow, Linda Chang, Gene-Jack Wang, Joanna S. Fowler, Yu-Sin Ding, Mark Sedler, Jean Logan, Dinko Franceschi, John Gatlery, Robert Hitzemann, Andrew Gifford, Christopher Wong, and Naomi Pappas

- 2022 Developmental sequence from disruptive behavior diagnosis to adolescent alcohol dependence**
Samuel Kuperman, Steven S. Schlosser, John R. Kramer, Kathleen Bucholz, Victor Hesselbrock, Theodore Reich, and Wendy Reich

- 2027 Ethnic disparities in unmet need for alcoholism, drug abuse, and mental health care**
Kenneth Wells, Ruth Klap, Alan Koike, and Cathy Sherbourne

- 2033 Cannabis abuse as a risk factor for depressive symptoms**
Gregory B. Bovasso

- 2038 Long-term outcome of cognitive behavior therapy versus relaxation therapy for chronic fatigue syndrome: a 5-year follow-up study**
Alicia Deale, Kaneez Husain, Trudie Chalder, and Simon Wessely

- 2043 An open-label trial of evidence-based cognitive behavior therapy for nightmares and insomnia in crime victims with PTSD**
Barry Krakow, Lisa Johnston, Dominic Melendrez, Michael Hollifield, Teddy D. Warner, Debie Chavez-Kennedy, and Margaret J. Herlan

- 2048 Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression**
Perry F. Renshaw, Aimee M. Parow, Fuyuki Hirashima, Yong Ke, Constance M. Moore, Blaise deB. Frederick, Maurizio Fava, John Hennen, and Bruce M. Cohen

- 2056 A study of women who stalk**
Rosemary Purcell, Michele Pathé, and Paul E. Mullen

- 2061 Prevalence of body dysmorphic disorder in a community sample of women**
Michael W. Otto, Sabine Wilhelm, Lee S. Cohen, and Bernard L. Harlow

NEW RESEARCH – BRIEF REPORTS

- 2064 Defective relationship between subjective experience and behavior in schizophrenia**
Jean-Marie Danion, Erick Gokalsing, Philippe Robert, Marilyne Massin-Krauss, and Elisabeth Bacon

- 2066 Measuring P50 suppression and prepulse inhibition in a single recording session**
Gregory A. Light and David L. Braff

- 2069 Neurophysiological evidence of corollary discharge dysfunction in schizophrenia**
Judith M. Ford, Daniel H. Mathalon, Theda Heinks, Sontine Kalba, William O. Faustman, and Walton T. Roth

2071 A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia

Wayne S. Fenton, Faith Dickerson, John Boronow, Joseph R. Hibbeln, and Michael Knable

2074 Influence of serotonin-transporter-linked promoter region polymorphism on platelet activation in geriatric depression

Ellen M. Whyte, Bruce G. Pollock, William R. Wagner, Benoit H. Mulsant, Robert E. Ferrell, Sati Mazumdar, and Charles F. Reynolds III

2077 Antidepressant treatment of depression in the Finnish general population

Tanja Laukkala, Erkki Isometsä, Juha Hämäläinen, Martti Heikkinen, Sari Lindeman, and Hillevi Aro

2080 Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low

Eugenii A. Rabiner, Zubin Bhagwagar, Roger N. Gunn, Peter A. Sargent, Christopher J. Bench, Philip J. Cowen, and Paul M. Grasby

2083 Cortisol feedback during the HPA quiescent period in patients with major depression

Joel A. Posener, Charles DeBattista, Gordon H. Williams, and Alan F. Schatzberg

The American Journal of Psychiatry is on-line at <http://ajp.psychiatryonline.org>